Publication Radar · Source metadata
TrialJev: Open-Weight Single Pass Eligibility Scoring for Patient Trial Screening
Publication record
Bibliographic evidence describes where and when a record appeared. It does not validate scientific claims.
First announced by arXiv: 2026-11-10 · Indexed by Pub-AI: 2026-11-10 UTC
TrialJev: Open-Weight Single Pass Eligibility Scoring for Patient Trial Screening
First announced by arXiv: 2026-11-10 · Original record ↗
- arxiv
- 2611.10145
Explicit source versions (1)
- v1 · Date not supplied
- Preprint available
Source date: 2026-11-10 · First detected: 2026-11-10 UTC · Historical baseline
Source evidence (1)
- Official evidence ↗ · RSS guid=oai:arXiv.org:2611.10145v1; arxiv:announce_type=new; item pubDate (official metadata)
Abstract · arxiv
Clinical trial screening requires assessing large numbers of patient-trial pairs to prioritize candidates for detailed eligibility review, often under restrictions on sharing patient records. We introduce TrialJev, an open-weight eligibility scorer that uses LoRA-adapted Qwen models and a pointer head to score natural-language answer options in a single forward pass, without autoregressive decoding. Trained on TREC Clinical Trials 2021 and evaluated on 6,975 eligible-or-excluded pairs from 50 unseen TREC 2022 synthetic patients, TrialJev achieves 80.97% (Qwen3.5-27B) and 81.84% (Qwen3.8-27B) accuracy, compared with 79.87% and 79.93% for LLMs fine-tuned on the same data to generate verdicts. In matched batch-1 measurements, verdict generation takes 2.45-2.70 times as long as the one-pass inference of TrialJev at 9B-27B. Under a common development-fitted decision correction, the two 27B TrialJev models reach 80.99% and 81.88% accuracy, compared with 81.28% for the proprietary hosted Jev API; paired confidence intervals include zero. TrialJev runs locally on a single GPU, requiring approximately 178 ms per pair at 27B, without transmitting patient text to an external model API. An A/B-logit ablation shows that avoiding decoding, rather than the pointer head alone, accounts for the measured efficiency advantage. TrialJev is intended for first-pass prioritization of candidate trials, complementing rather than replacing explanatory models and clinical review. Evaluation is limited to synthetic patients and implementation-specific timing, and clinical use has not been validated. Adapters, pointer heads, and model cards are released on Hugging Face.
